Chapter: 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY
2.1 CXO perspective
2.2 Market beyond: what to expect by 2025
2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario

Chapter: 3 BIOPSY DEVICE MARKET OVERVIEW
3.1 Market definition and scope
3.2 Market Dynamics
3.2.1 Top impacting factors
3.2.2 Drivers
3.2.3 Restrains
3.2.4 Top winning strategies

3.3 Porters Five Forces analysis
3.3.1 Fewer suppliers lead to higher bargaining power of suppliers
3.3.2 Higher concentration of buyers leads to low bargaining power
3.3.3 High threat of substitutes due to presence of minimal invasive diagnostic procedures
3.3.4 Low threat of new entrants due to high capital investment
3.3.5 Moderate competitive rivalry

3.4 Value chain analysis
3.4.1 Research and product development
3.4.2 Product testing
3.4.3 Manufacturing
3.4.4 End users

3.5 Regulatory norms
3.5.1 Regulatory issues of gastroenterology and urology biopsy devices in North America
3.5.2 Regulatory Scenario for breast biopsy in European Union

3.6 Reimbursement scenario
3.6.1 Reimbursement for Breast Cancer Screening in the U.S.
3.6.2 Reimbursement for Breast Reconstruction or Prosthesis

3.7 Patent analysis
3.7.1 The U.S.: Patent analysis, by market participants
3.7.2 Europe: Patent analysis, by market participant
3.7.3 Japan: Patent analysis, by market participants

Chapter: 4 MARKET BY TYPE
4.1 Overview
4.1.1 Market size and forecast

4.2 Breast biopsy devices
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.2.4 Types of breast biopsy devices
4.2.4.1 VacuumAssisted Biopsy (VAB) devices
4.2.4.1.1 Market size and forecast
4.2.4.2 Core Needle Biopsy (CNB)
4.2.4.2.1 Market size and forecast
4.2.4.3 Fine Needle Aspiration Biopsy
4.2.4.3.1 Market size and forecast

4.4 Gastro Intestinal biopsy devices
4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast

4.5 Soft tissue biopsy devices
4.5.1 Key market trends
4.5.2 Key growth factors and opportunities
4.5.3 Market size and forecast

4.6 Bronchial biopsy devices
4.6.1 Key market trends
4.6.2 Key growth factors and opportunities
4.6.3 Market size and forecast

4.7 Gynaecological Biopsy Devices
4.7.1 Key market trends
4.7.2 Key growth factors and opportunities
4.7.3 Market size and forecast

4.8 Robotic Guidance Systems
4.8.1 Key market trends
4.8.2 Key growth factors and opportunities
4.8.3 Market size and forecast

4.9 Others
4.9.1 Key market trends
4.9.2 Key growth factors and opportunities
4.9.3 Market size and forecast

Chapter: 5 MARKET BY APPLICATION
5.1 Overview
5.1.1 Market size and forecast

5.2 Breast Biopsy
5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size and forecast

5.3 Gastroenterology Biopsy
5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size and forecast

5.4 Prostate Biopsy
5.4.1 Key market trends
5.4.2 Key growth factors and opportunities
5.4.3 Market size and forecast

5.5 Liver biopsy
5.5.1 Key market trends
5.5.2 Key growth factors and opportunities
5.5.3 Market size and forecast

5.6 Lung biopsy
5.6.1 Key market trends
5.6.2 Key growth factors and opportunities
5.6.3 Market size and forecast

5.7 Kidney Biopsy
5.7.1 Key market trends
5.7.2 Key growth factors and opportunities
5.7.3 Market size and forecast

5.8 Gynaecological Biopsy
5.8.1 Key market trends
5.8.2 Key growth factors and opportunities
5.8.3 Market size and forecast

5.9 Others
5.9.1 Market size and forecast

Chapter: 6 MARKET BY IMAGE GUIDED TECHNOLOGY
6.1 Overview
6.1.1 Market size and forecast

6.2 MRIguided biopsy
6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast

6.3 StereotacticGuided Breast Biopsy
6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Market size and forecast

6.4 UltrasoundGuided Biopsy
6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast

6.5 CT guided biopsy
6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast
6.6 Others (positron emission mammography (PEM) imaging technology, Xray technology and RX technology)
6.6.1 Market size and forecast

Chapter: 7 MARKET BY END USERS
7.1 Overview
7.1.1 Market size and forecast

7.2 Diagnostic Centers
7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.3 Market size and forecast

7.3 Hospitals
7.3.1 Key market trends
7.3.2 Key growth factors and opportunities
7.3.3 Market size and forecast

Chapter: 8 MARKET BY GEOGRAPHY
8.1 Overview
8.1.1 Market size and forecast

8.2 North America
8.2.1 Key market trends
8.2.2 Key growth factors and opportunities
8.2.3 Market size and forecast

8.3 Europe
8.3.1 Key market trends
8.3.2 Key growth factors and opportunities
8.3.3 Market size and forecast

8.4 Asia-Pacific
8.4.1 Key market trends
8.4.2 Key growth factors and opportunities
8.4.3 Market size and forecast

8.5 LAMEA
8.5.1 Key market trends
8.5.2 Key growth factors and opportunities
8.5.3 Market size and forecast

Chapter: 9 COMPANY PROFILES
9.1 Leica Biosystems (Devicor Medical products, inc.)
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Biopsy Product Portfolio
9.1.4 Strategic moves and developments
9.1.5 SWOT analysis of Leica Biosystems

9.2 Boston Scientific Corporation
9.2.1 Overview
9.2.2 Boston Scientific Corporation snapshot
9.2.3 Operating Business Segment Overview
9.2.4 Business performance
9.2.5 Biopsy Product Portfolio
9.2.6 Strategic moves and developments
9.2.7 SWOT analysis

9.3 Cook Medical, Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Biopsy product portfolio
9.3.4 Strategic moves and developments
9.3.5 SWOT analysis of Cook Medical

9.4 Hologic, Inc.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Business performance
9.4.4 Biopsy Product Portfolio
9.4.5 Strategic moves and developments
9.4.6 SWOT analysis of Hologic Inc.

9.5 Mauna kea technologies.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Business performance
9.5.4 Biopsy product portfolio
9.5.5 Strategic moves and developments
9.5.6 SWOT analysis of Mauna Kea Technologies

9.6 Becton Dickinson and Company (Carefusion Corp.)
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Business performance
9.6.4 Biopsy product portfolio
9.6.5 Strategic moves and developments
9.6.6 SWOT analysis of Beckton Dickinson and Company

9.7 C. R. BARD, INC.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Business performance
9.7.4 Biopsy Product Portfolio
9.7.5 SWOT analysis of C.R. Bard, Inc.

9.8 Fujifilm Holdings Corp.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Business performance
9.8.4 Strategic moves and developments
9.8.5 SWOT analysis of Fujifilm Holdings Corp.

9.9 Veran Medical Technologies
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Biopsy product portfolio
9.9.4 Strategic moves and development
9.9.5 SWOT analysis of Integrated DNA Technologies, Inc.

9.10 Cardinal Health, Inc.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Business performance
9.10.4 Biopsy product portfolio
9.10.5 Strategic moves and development
9.10.6 SWOT analysis of Cardinal Health Inc.